Abstracts - faqs.org

Abstracts

Zoology and wildlife conservation

Search abstracts:
Abstracts » Zoology and wildlife conservation

Playing dirty

Article Abstract:

Gleevec, a leukaemia treatment made by Swiss drug company Novartis was designed to zero in on a single protein in cancerous cells, specifically killing them while leaving healthy cells unharmed and was proved to spectacularly effective and non-toxic. Latter its was revealed that the drug works by attaching to a key part of an overactive protein that causes chronic myeloid leukaemic and inhibits a second protein, PDGF receptor.

Author: Frantz, Simon
Publisher: Macmillan Publishing Ltd.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 2005
Switzerland, In-Vitro Diagnostic Substance Manufacturing, Diagnostic substances, Leukemia Diagnostics, Novartis AG, NVTSY, Gleevec (Medication), Leukemia diagnostic reagents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Reinventing an industry

Article Abstract:

The year January 2005 brought India into compliance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS), which are international rules that forbid the copying of patented drugs. Biocon a Bangalore-based company launched BIOMAb-EGFR, the first new drug to be developed, tested and taken through approval by an Indian company, which could be the start of a more innovative future for India's drug industry.

Author: Mandavilli, Apoorva
Publisher: Macmillan Publishing Ltd.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 2007
Patents & copyrights, India, Intellectual property, Biocon India

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Chasing shadows

Article Abstract:

A painkiller drug, Vioxx has caused adverse effects on the people thus questioning the safety system and the Food and Drug Administration (FDA). Critics argue that the FDA needs to re-examine its priorities in light of the Vioxx scare.

Author: Frantz, Simon
Publisher: Macmillan Publishing Ltd.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 2005
United States, Product standards, safety, & recalls, Management dynamics, Management, Product defects and recalls, Powers and duties, Company business management, United States. Food and Drug Administration, Drug approval, Vioxx (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Product development, Pharmaceutical industry
Similar abstracts:
  • Abstracts: Something to see. Champing at the bit. 'Fingerprinting' documents and packaging
  • Abstracts: On being a birder...or not. Fishing for enlightenment. Ambassador from the roof of the world
  • Abstracts: The lights in the forest. Final song for an unsung hero. Caught in the crossfire: Part II
  • Abstracts: Phase-locking in double-point-contact spin-transfer devices. An organic thyristor
  • Abstracts: Molecular gas and dust around a radio-quiet quasar at redshift 4.69. Discovery of a bright quasar without a massive host galaxy
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.